"10.1371_journal.pone.0061359","plos one","2013-05-01T00:00:00Z","Carey K Anders; Barbara Adamo; Olga Karginova; Allison M Deal; Sumit Rawal; David Darr; Allison Schorzman; Charlene Santos; Ryan Bash; Tal Kafri; Lisa Carey; C Ryan Miller; Charles M Perou; Norman Sharpless; William C Zamboni","Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America; Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States of America; Department of Human Pathology, Integrated Therapies in Oncology Unit, University of Messina, Messina, Italy; Department of Biostatistics, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States of America; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, United States of America; Translational Oncology and Nanoparticle Drug Development Initiative (TOND2I) Lab, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America; Gene Therapy Center and Department of Microbiology and Immnunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, United States of America; Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, United States of America; Carolina Center of Cancer Nanotechnology Excellence, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America; Institute of Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America","Performed in vitro studies, IC50: BA. Performed in vitro studies, cell prep for in vivo model: OK. Performed cell line transduction: TK. Performed in vivo studies: DD SR AS CS RB. Peformed Pharmacologic Assays: SR AS WZ. Reviewed the manuscript critically for important intellectual content: CKA BA OK AD SR DD AS CS RB TK LC CRM CMP NS WZ. Read and approved the final manuscript: CKA BA OK AD SR DD AS CS RB TK LC CRM CMP NS WZ. Conceived and designed the experiments: CKA BA OK DD LC CMP NS WZ. Performed the experiments: BA OK TK DD SR AS CS RB. Analyzed the data: CKA BA OK AD SR CS DD. Contributed reagents/materials/analysis tools: CKA BA OK DD SR AS CS RB TK CMP NS WZ. Wrote the paper: CKA BA OK AD SR DD AS CS RB TK LC CRM CMP NS WZ.","The authors have declared that no competing interests exist.","2013","05","Carey K Anders","CKA",15,FALSE,8,1,7,15,TRUE,TRUE,FALSE,0,NA,FALSE
